AACR: New CAR T cell therapy benefits patients with advanced...
Phase I trial demonstrates lasting responses and encouraging safety profile in two aggressive thyroid cancer subtypes, suggesting...
AACR: HER2 targeted therapy shows promise in previously...
Zongertinib, a HER2-targeted therapy made by Boehringer Ingelheim, demonstrated promising results in HER2-mutant lung cancer.
...
...
AACR: Topical gel relieves painful skin rash side effect...
Novel treatment allowed patients with colorectal cancer to successfully continue taking their cancer treatment with improved quality...
AACR: First-in-class covalent Werner helicase inhibitor shows...
RO7589831, a new drug from Roche, is first in a new class of drugs called Werner helicase inhibitors
Drug works similarly to other...
AACR: Olaparib and pembrolizumab combination shows early...
Combining Lynparza (olaparib) and Keytruda (pembrolizumab) showed antitumor activity in multiple cancer types, particularly those with...
AACR: Researchers share promising results from MD Anderson...
ABSTRACTS: CT012, CT132, CT265
Researchers from The University of Texas MD Anderson Cancer Center will present promising...
AACR: MD Anderson researchers share cancer breakthroughs
ABSTRACTS: 1186, 3746, 3763, 3776, 3824, 6367, 6384, 6396, 6424, 6427, 6436, 6438,
CHICAGO ― Researchers from The University of...
AACR: Five MD Anderson researchers honored with 2025...
Five scientists from The University of Texas MD Anderson Cancer Center will be recognized with Scientific Achievement Awards and...
AACR: MD Anderson’s John Weinstein elected Fellow of the...
CHICAGO ― John N. Weinstein, M.D., Ph.D., chair of Bioinformatics and Computational Biology and professor of Systems Biology...
NK cells complexed with bispecific antibody yield high...
HOUSTON ― A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a...